Skip to main content

Together we are beating cancer

Donate now

Cancer News

The latest news, analysis and opinion from Cancer Research UK

Search Results: PARP

Showing 12 out of 141 results

The first episode features Ruth Plummer. Ruth is Professor of Experimental Cancer Medicine at Newcastle University and Director of the CRUK Newcastle Cancer Centre. She talks about how the DNA repair inhibition field has changed over 20 years, her instrumental role in the development of the PARP inhibitor Rucaparib and why work/life balance is so important for the future of research life. The first episode features Ruth Plummer. Ruth is Professor of Experimental Cancer Medicine at Newcastle University and Director of the CRUK Newcastle Cancer Centre. She talks about how the DNA repair inhibition field has changed over 20 years, her instrumental role in the development of the PARP inhibitor Rucaparib and why work/life balance is so important for the future of research life.

by Phil Prime | Podcast | 4 February 2022

4 February 2022

This entry is part 1 of 9 in the series Cancer Research Matters - series 1
Patient photo

How researchers supported by Cancer Research UK pioneered the development of PARP inhibitors. How researchers supported by Cancer Research UK pioneered the development of PARP inhibitors.

by Liam Drew | Research Feature | 24 September 2020

24 September 2020

PARP and inhibitor

Olaparib is the first PARP inhibitor to move closer to licensing in Europe. What is it, how does it work, and when will it be available in the UK? Olaparib is the first PARP inhibitor to move closer to licensing in Europe. What is it, how does it work, and when will it be available in the UK?

by Kat Arney | Analysis | 24 October 2014

24 October 2014

Breast cancer cells

Olaparib, a targeted cancer drug discovered and developed with our funding, has been approved for hundreds of patients with certain breast and prostate cancers in England.  Olaparib, a targeted cancer drug discovered and developed with our funding, has been approved for hundreds of patients with certain breast and prostate cancers in England. 

by Tim Gunn | News | 11 April 2023

11 April 2023

Glioblastoma cells seen through a microscope.

We've helped double brain tumour survival over the past 40 years. Now, researchers are combining some of our most successful drugs, temozolomide and PARP inhibitors, to make glioblastoma treatment more effective. We've helped double brain tumour survival over the past 40 years. Now, researchers are combining some of our most successful drugs, temozolomide and PARP inhibitors, to make glioblastoma treatment more effective.

by Tim Gunn | Analysis | 13 February 2023

13 February 2023

Headshots of Ruth Plummer, Eve Wiltshaw and Judith Bliss

As our 20th anniversary year draws to a close, we're celebrating some of the pioneering women who have contributed to impactful cancer research and paved the way for even more. As our 20th anniversary year draws to a close, we're celebrating some of the pioneering women who have contributed to impactful cancer research and paved the way for even more.

by Amy Warnock | In depth | 18 January 2023

18 January 2023

A sculpture of a tumour made as part of the Science Museum exhibition
  • Health & Medicine
  • Science & Technology

Our most important cancer research stories of 2022

This year has been full of research, advances and people worth celebrating. Here are some of our biggest stories from the past 12 months.  This year has been full of research, advances and people worth celebrating. Here are some of our biggest stories from the past 12 months. 

by Tim Gunn | In depth | 14 December 2022

14 December 2022

A prostate cancer cell.

NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective

by Jacob Smith | News | 13 September 2022

13 September 2022